868 abstracts found.



Results filter

Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA

Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

Breast cancer as a disease of self-seeding: concept, evidence, and clinical implications

Year:

Session type:

Larry Norton
Memorial Sloan-Kettering Cancer Center, New York, USA

Role of telomeres in cancer and aging

Year:

Session type:

Maria A Blasco
Spanish National Cancer Centre (CNIO), Madrid, Spain

Drugging the cancer genome: design of personalised cancer medicines

Year:

Session type:

Paul Workman
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK

Synthetic lethal approaches to the development of new therapies for cancer

Year:

Session type:

Alan Ashworth
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

Difficult decisions: end of life care or assisted suicide?

Year:

Session type:

Ilora Finlay
Cardiff University, UK

Tumour suppressors and hypoxia pathways in cancer

Year:

Session type:

Peter Ratcliffe
University of Oxford, UK

Evolution of the cancer clinical trial over three decades: problems of design, analysis, reporting and interpretation

Year:

Session type:

Ian Tannock
Princess Margaret Hospital, Toronto, Canada

Complexity of clonal architecture in childhood leukaemia: Darwin re-visited

Year:

Session type:

Mel Greaves
The Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK

The Bcl-2 family in cancer development and cancer treatment

Year:

Session type:

Suzanne Cory
The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Australia

The use of biomarkers in cancer clinical trials

Year:

Session type:

Marc Buyse
International Drug Development Institute, Brussels, Belgium

Using mice to model cancer cures

Year:

Session type:

Gerard Evan
UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, USA